Blinatumomab
- Generic Name
- Blinatumomab
- Brand Names
- Blincyto
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 853426-35-4
- Unique Ingredient Identifier
- 4FR53SIF3A
- Background
Blinatumomab is a BiTE-class (bi-specific T-cell engager) constructed monoclonal antibody formed by the recombinant fusion of an anti-CD3 single-chain variable fragment (scFV) and an anti-CD19 scFV through a short peptide linker. CD3 is an antigen expressed on the surface of T-cells, while CD19 is mostly expressed on the surface of malignant B-cells. Since b...
- Indication
Blinatumomab is indicated for the treatment of adults and children with relapsed or refractory CD19-positive B-cell precursor acute lymphoblastic leukemia (ALL). It is also indicated in adults and children for the treatment of CD19-positive B-cell precursor ALL in first or second complete remission with minimal residual disease (MRD) greater than or equal to...
- Associated Conditions
- Precursor B-lymphoblastic leukaemia acute, Refractory B-cell precursor acute lymphoblastic leukemia, Relapsed B cell precursor Acute lymphoblastic leukemia
- Associated Therapies
- -
D-ALBA Frontline Sequential Dasatinib and Blinatumomab in Adult Philadelphia Positive Acute Lymphoblastic Leukemia
- First Posted Date
- 2016-04-20
- Last Posted Date
- 2018-03-22
- Target Recruit Count
- 60
- Registration Number
- NCT02744768
- Locations
- 🇮🇹
Az.Ospedaliera S.G.Moscati, Avellino, Italy
🇮🇹Ospedale Niguarda " Ca Granda" - SC Ematologia Blocco SUD, Ponti Est, Scala E, 4° piano, Milano, Italy
🇮🇹Azienda Ospedaliera di Rilievo Nazionale "A. Cardarelli", Napoli, Italy
Lenalidomide and Blinatumomab for the Treatment of Relapsed Non-Hodgkin Lymphoma
- Conditions
- Recurrent Burkitt LymphomaRecurrent Diffuse Large B-Cell LymphomaRecurrent Grade 1 Follicular LymphomaRecurrent Grade 3 Follicular LymphomaRecurrent Grade 3a Follicular LymphomaRecurrent Grade 3b Follicular LymphomaRecurrent Grade 2 Follicular LymphomaRecurrent Gray-Zone LymphomaRecurrent Mantle Cell LymphomaRecurrent Marginal Zone Lymphoma
- Interventions
- First Posted Date
- 2015-10-06
- Last Posted Date
- 2024-12-05
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 44
- Registration Number
- NCT02568553
- Locations
- 🇺🇸
Los Angeles General Medical Center, Los Angeles, California, United States
🇺🇸University of Kansas Hospital-Westwood Cancer Center, Westwood, Kansas, United States
🇺🇸City of Hope Comprehensive Cancer Center, Duarte, California, United States
Study of Blinatumomab in Japanese Patients With Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia
- Conditions
- Interventions
- First Posted Date
- 2015-04-09
- Last Posted Date
- 2022-12-12
- Lead Sponsor
- Amgen
- Target Recruit Count
- 66
- Registration Number
- NCT02412306
- Locations
- 🇯🇵
Kyushu University Hospital, Fukuoka-shi, Fukuoka, Japan
🇯🇵National Hospital Organization Nagoya Medical Center, Nagoya-shi, Aichi, Japan
🇯🇵Osaka City General Hospital, Osaka-shi, Osaka, Japan
Phase 3 Trial of Blinatumomab vs Standard Chemotherapy in Pediatric Subjects With HIgh-Risk (HR) First Relapse B-precursor Acute Lymphoblastic Leukemia (ALL)
- First Posted Date
- 2015-03-20
- Last Posted Date
- 2024-05-29
- Lead Sponsor
- Amgen
- Target Recruit Count
- 111
- Registration Number
- NCT02393859
- Locations
- 🇬🇧
Research Site, Sutton, United Kingdom
Expanded Access Protocol - Blinatumomab in Pediatric & Adolescent Subjects With Relapsed/Refractory B-precursor ALL
- First Posted Date
- 2014-07-11
- Last Posted Date
- 2024-05-13
- Lead Sponsor
- Amgen
- Registration Number
- NCT02187354
- Locations
- 🇬🇧
Research Site, Sheffield, United Kingdom
Blinatumomab and Combination Chemotherapy or Dasatinib, Prednisone, and Blinatumomab in Treating Older Patients With Acute Lymphoblastic Leukemia
- Conditions
- Interventions
- Procedure: BiopsyProcedure: Biospecimen CollectionBiological: BlinatumomabProcedure: Bone Marrow Aspiration and BiopsyProcedure: Computed TomographyProcedure: EchocardiographyDrug: DasatinibProcedure: Lumbar PunctureProcedure: Magnetic Resonance ImagingDrug: MercaptopurineDrug: MethotrexateDrug: Methotrexate SodiumDrug: PrednisoneDrug: VincristineDrug: Vincristine SulfateProcedure: X-Ray Imaging
- First Posted Date
- 2014-05-21
- Last Posted Date
- 2024-12-04
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 53
- Registration Number
- NCT02143414
- Locations
- 🇺🇸
Springfield Memorial Hospital, Springfield, Illinois, United States
🇺🇸University of Arizona Cancer Center-North Campus, Tucson, Arizona, United States
🇺🇸John L McClellan Memorial Veterans Hospital, Little Rock, Arkansas, United States
Blinatumomab in Treating Younger Patients With Relapsed B-cell Acute Lymphoblastic Leukemia
- Conditions
- Interventions
- Procedure: Allogeneic Hematopoietic Stem Cell TransplantationBiological: BlinatumomabDrug: AsparaginaseDrug: CyclophosphamideDrug: CytarabineDrug: DexamethasoneOther: Pharmacological StudyDrug: EtoposideDrug: Leucovorin CalciumDrug: MercaptopurineDrug: MethotrexateDrug: MitoxantroneDrug: Mitoxantrone HydrochlorideRadiation: Radiation TherapyDrug: PegaspargaseDrug: Therapeutic HydrocortisoneDrug: ThioguanineDrug: VincristineDrug: Vincristine Sulfate
- First Posted Date
- 2014-04-02
- Last Posted Date
- 2024-11-13
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 669
- Registration Number
- NCT02101853
- Locations
- 🇺🇸
Johns Hopkins University/Sidney Kimmel Cancer Center, Baltimore, Maryland, United States
🇺🇸NYP/Weill Cornell Medical Center, New York, New York, United States
🇺🇸State University of New York Upstate Medical University, Syracuse, New York, United States
Blinatumomab Versus Standard of Care Chemotherapy in Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia (ALL)
- Conditions
- Interventions
- First Posted Date
- 2013-12-17
- Last Posted Date
- 2024-03-05
- Lead Sponsor
- Amgen
- Target Recruit Count
- 405
- Registration Number
- NCT02013167
- Locations
- 🇬🇧
Research Site, Sutton, United Kingdom
Combination Chemotherapy With or Without Blinatumomab in Treating Patients With Newly Diagnosed BCR-ABL-Negative B Lineage Acute Lymphoblastic Leukemia
- Conditions
- Interventions
- Procedure: Allogeneic Hematopoietic Stem Cell TransplantationProcedure: Biospecimen CollectionBiological: BlinatumomabProcedure: Bone Marrow AspirationProcedure: Bone Marrow BiopsyDrug: CyclophosphamideDrug: CytarabineDrug: DaunorubicinDrug: Daunorubicin HydrochlorideDrug: DexamethasoneDrug: EtoposideDrug: Leucovorin CalciumProcedure: Lumbar PunctureDrug: MercaptopurineDrug: MethotrexateDrug: PegaspargaseDrug: PrednisoneBiological: RituximabDrug: VincristineDrug: Vincristine SulfateProcedure: X-Ray Imaging
- First Posted Date
- 2013-12-06
- Last Posted Date
- 2024-12-05
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 488
- Registration Number
- NCT02003222
- Locations
- 🇺🇸
Banner North Colorado Medical Center, Greeley, Colorado, United States
🇺🇸Good Samaritan Hospital - Cancer Centers of Colorado, Lafayette, Colorado, United States
🇺🇸Banner McKee Medical Center, Loveland, Colorado, United States
Blinatumomab in Adults With Relapsed/Refractory Philadelphia Positive B-precursor Acute Lymphoblastic Leukemia
- Conditions
- Interventions
- First Posted Date
- 2013-12-04
- Last Posted Date
- 2024-05-28
- Lead Sponsor
- Amgen
- Target Recruit Count
- 45
- Registration Number
- NCT02000427
- Locations
- 🇬🇧
Research Site, Sutton, United Kingdom
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.